Embecta (STU:JX7) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:JX7 Embecta Corp STU:JX7
52 GF Score
Price €4.40
GF Value €10.64
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Embecta Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Embecta Quality Rank Related Terms

STU:JX7
52GF Score
Embecta Corp STU:JX7
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Embecta (STU:JX7) Overvalued in 2026?

Based on GuruFocus' analysis, Embecta stock appears to be undervalued. The current stock price of €4.40 is trading 58.7% below its estimated GF Value™ of €10.64. GuruFocus considers Embecta to be Possible Value Trap.

Key valuation signals for STU:JX7:

  • Quality Rank:
  • GF Value™: €10.64 vs. price of €4.40 (58.7% below fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the STU:JX7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Embecta Business Description

Other Exchanges EMBC:USA
Address 300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
52GF Score

Get the complete analysis for STU:JX7

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.40
Price
€10.64
GF Value